Parkinson's Disease Therapy adherence Medication Ziekte van Parkinson Therapietrouw Medicatie
Conditions
Interventions
This study is a prospective randomized controlled trial (RCT) with a follow up of 3 months. The interventions, Medido versus usual care, are randomly assigned to the patients and will be stratified by
possibly a capsule will be used. Changes in medication use during the study are passed on to the pharmacist, which is regular care. Subsequently, the baxtered medication can be changed. When is it nee
Sponsors
Mw. L. ter Brake-Berning, nurse practitioner Parkinson en Mw L. Vree Egberts, researcher
Eligibility
Inclusion criteria
Inclusion criteria: The patient: 1. Is older than forty years; 2. Has four or more medication intake moments a day, including non-parkinson medication; 3. Has on-off fluctuations when Parkinson medication is not taken; 4. Has given consent to participate in the study; 5. Is diagnosed with Parkinson’s disease; 6. Will be treated at Medisch Spectrum Twente at Enschede or ZiekenhuisGroep Twente at Hengelo or Almelo; 7. May receive personal at-home care.
Exclusion criteria
Exclusion criteria: Patients: 1. Not capable of completing the questionnaires; 2. Whose medication is administered by other persons, excluding patients with personal at-home care givers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary parameter of this study is the physical disability of Parkinson’s patients. To measure the physical disability, the AMC Linear Disability Score (ALDS) will be used. The ALDS checks the activities in daily life of the patient. The ALDS is a flexible, validated and clinimetrically sound and flexible instrument to assess the level of disability in patients with Parkinson’s disease. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Does the use of Medido improve the Quality of life of Parkinson’s patients compared with the current method of medication distribution to Parkinson’s patients after a follow-up period of 3 months, as measured by the PDQ39 questionnaire; 2. What is the cost effectiveness ratio expressed in Cost per QALY of the Medido for Parkinson’s patients relative to current treatment for Parkinson’s patients, as measured by the Euroqol 5D (EQ5D); 3. What is the Quality of life for personal care givers for Parkinson’s patients for care givers in the Medido group versus regular care group, as measured by the PDQ carer questionnaire; 4. What is the patient experience of motor symptoms in the Medido group versus regular care group, as measured by the Visual Analog Scale (VAS); 5. How many times do you have a off-period during the day, as measured by the MDS-UPDRS. | — |
Contacts
Public ContactJ. Palen, van der
Medisch Spectrum Twente, P.O. Box 50000
Outcome results
None listed